|Bid||0.0000 x 800|
|Ask||0.0000 x 1400|
|Day's Range||4.4600 - 4.7000|
|52 Week Range||4.3800 - 51.6000|
|Beta (3Y Monthly)||2.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.07|
The company’s future on the Nasdaq hangs in the balance, as its share price continues to sit below a buck in the wake of a delisting threat from the exchange.
The big shareholder groups in Novavax, Inc. (NASDAQ:NVAX) have power over the company. Institutions often own shares...
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]
Novavax (NVAX) seeks to use accelerated approval pathway for its influenza vaccine candidate, NanoFlu, in the United States.
An accelerated pathway would help the company conduct a non-inferiority immunogenicity trial against a licensed quadrivalent comparator, while making a commitment to confirm its efficacy post-licensure.
The biotech will turn over two of its Gaithersburg manufacturing facilities and equipment to Paragon Bioservices Inc., now part of New Jersey-based Catalent Inc.
Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will utilize the accelerated approval pathway for licensure for NanoFlu™, its nanoparticle seasonal influenza vaccine candidate. The U.S. Food and Drug Administration (FDA) acknowledged in a recent letter that the accelerated approval pathway is available to Novavax for its NanoFlu vaccine. Novavax expects to initiate its pivotal Phase 3 clinical trial by the fall of 2019 with top-line clinical data expected in the first quarter of 2020.
Manufacturing equipment and related assets to be sold to Catalent’s Paragon Gene Therapy for $18 million in cashOver 100 manufacturing and quality employees to join.
FDA recommends Novavax (NVAX) to conduct additional phase III study for its respiratory syncytial virus (RSV) vaccine candidate for infants, ResVax.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 10) Abbott Laboratories (NYSE: ABT ) BIO-TECHNE Corp (NASDAQ: ...
Novavax, Inc. (NVAX) a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced updates on the pursuit of global licensure for ResVax™ following the Prepare™ Phase 3 clinical trial. The U.S. Food & Drug Administration (FDA) has recommended that Novavax conduct an additional Phase 3 clinical trial to confirm efficacy against medically significant RSV disease in infants born to mothers vaccinated with ResVax. Novavax has recently held meetings with several European national regulatory agencies to solicit input on the Prepare trial and possible pathways to licensure in Europe. The next step will be to seek formal scientific advice this fall from the European Medicines Authority (EMA), the agency responsible for licensing vaccines for the European Union.
It’s official: Novavax Inc. will have to complete another clinical trial for its respiratory syncytial virus vaccine candidate for infants, ResVax, lengthening its road to market by roughly three years following its failed phase 3 trial in March. The Gaithersburg biotech has received a letter from the Food and Drug Administration indicating another trial is required before it can earn clearance, said Novavax CEO Stanley Erck in an interview. “We are still heavily focused on RSV,” Erck said, adding: “Yes, it’s going to take a couple years longer and more money than we hoped." The news marks a pivotal moment for Novavax (NASDAQ: NVAX) as it works its way down the regulatory pathways in the U.S. and abroad after ResVax failed to prevent RSV in newborns through maternal immunizations at a high-enough rate in its late-stage trial.
GAITHERSBURG, Md., June 04, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced that John J. Trizzino, Senior Vice President, Chief Business Officer and Chief Financial.
GAITHERSBURG, Md., May 10, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced an adjustment to the conversion rate applicable to its existing 3.75% Convertible Senior Notes.
The company will put into effect a reverse stock split of its issued and outstanding common stock, a move intended to increase its share price.
Novavax, Inc. (NVAX) today announced it will effect a one-for-twenty reverse stock split of its issued and outstanding common stock. Stockholders of Novavax approved an amendment to Novavax’ Second Amended and Restated Certificate of Incorporation (the Amended Certificate) to effect the reverse stock split at a Special Meeting of Stockholders held on May 8, 2019. The reverse stock split is intended to give Novavax greater flexibility in considering and planning for future potential business needs and to increase the per share trading price of the Novavax’ common stock to enable Novavax to satisfy the minimum price requirement for continued listing on the Nasdaq Global Select Market.
Is Novavax an Attractive Pick after First-Quarter Results?(Continued from Prior Part)Nanoflu vaccine updatesOn January 3, Novavax (NVAX) issued a press release announcing positive top-line results from a Phase 2 trial that compared multiple
Is Novavax an Attractive Pick after First-Quarter Results?(Continued from Prior Part)Resvax vaccine updatesOn February 28, Novavax (NVAX) issued a press release announcing results from the first-ever Phase 3 trial for PrepareTM, evaluating the
Is Novavax an Attractive Pick after First-Quarter Results?Stock price movementsNovavax (NVAX) reported first-quarter results on May 2. The company reported revenues of $3.98 billion in the first quarter, a YoY decline of 58.75% and $0.62 million